ESR1 Mutated Metastatic Breast Cancer Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Radius Pharmaceuticals/ Menarini Group

DelveInsight’s “ESR1 Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The ESR1 Mutated Metastatic Breast Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the ESR1 Mutated Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ESR1 Mutated Metastatic Breast Cancer Market Insights

ESR1 Mutated Metastatic Breast Cancer Overview

Metastatic breast cancer is essentially a Stage IV breast cancer wherein cancer originates in breast tissue and then spreads to other body parts. The steroid hormone, estradiol, plays a vital role in breast cancer progression, and a majority of human breast cancers start as estrogen-dependent and express the estrogen receptor (ER).ERα is the major ER subtype in the mammary epithelium and plays a critical role in mammary gland biology and breast cancer progression.

Some of the key facts of the ESR1 Mutated Metastatic Breast Cancer Market Report: 

• The ESR1 Mutated Metastatic Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2021, it was estimated that the total diagnosed prevalent cases of HR positive breast cancer in the 7MM were 1,178,674
• It was noted that among diagnosed prevalent cases of HR positive breast cancer in the 7MM, maximum number of cases were occupied by the United States (505,337), in 2021
• On August 17, 2022. Sanofi discontinued the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD)
• In the 7MM, the diagnosed prevalent cases of metastatic breast cancer were 347,709 in 2021. These cases included early stage cases which progressed to metastatic stage
• In August 2022, Zentalis announced that they discontinued the clinical development of ZN-c5, its oral SERD, and ZN-e4, its EGFR inhibitor, following completion of its existing clinical trials, which are closed to accrual, in these two programs
• On Jan 2023, FDA approved Orserdu to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
• Key ESR1 Mutated Metastatic Breast Cancer Companies: Radius Pharmaceuticals/ Menarini Group, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, Eisai, Sun Pharma Advanced Research Company, Olema Pharmaceuticals, AstraZeneca, and others
• Key ESR1 Mutated Metastatic Breast Cancer Therapies: Elacestrant (RAD1901), ZB716, ARV-471, Lasofoxifene, H3B-6545, SCO-120, OP1250, Camizestrant (AZD983), and others

Get a Free sample for the ESR1 Mutated Metastatic Breast Cancer Market Report –

https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market

Key benefits of the ESR1 Mutated Metastatic Breast Cancer Market report:

1. ESR1 Mutated Metastatic Breast Cancer market report covers a descriptive overview and comprehensive insight of the ESR1 Mutated Metastatic Breast Cancer Epidemiology and ESR1 Mutated Metastatic Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The ESR1 Mutated Metastatic Breast Cancer market report provides insights on the current and emerging therapies.
3. ESR1 Mutated Metastatic Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The ESR1 Mutated Metastatic Breast Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the ESR1 Mutated Metastatic Breast Cancer market.

Download the report to understand which factors are driving ESR1 Mutated Metastatic Breast Cancer epidemiology trends @ ESR1 Mutated Metastatic Breast Cancer Epidemiological Insights 

ESR1 Mutated Metastatic Breast Cancer Market  

The dynamics of the ESR1 Mutated Metastatic Breast Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Upcoming therapies such as Camizestrant (AZD9833) + Palbociclib, elacestrant, SCO-120and others have the potential to create a significant positive shift in the ESR1 Mutated Metastatic Breast Cancer Cancer market.”

ESR1 Mutated Metastatic Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

ESR1 Mutated Metastatic Breast Cancer Epidemiology Segmentation:

The ESR1 Mutated Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of ESR1 Mutated Metastatic Breast Cancer
• Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer by severity
• Gender-specific Prevalence of ESR1 Mutated Metastatic Breast Cancer
• Diagnosed Cases of Episodic and Chronic ESR1 Mutated Metastatic Breast Cancer

ESR1 Mutated Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ESR1 Mutated Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers ESR1 Mutated Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the ESR1 Mutated Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major ESR1 Mutated Metastatic Breast Cancer market share @ ESR1 Mutated Metastatic Breast Cancer market forecast 

ESR1 Mutated Metastatic Breast Cancer Therapies and Key Companies

• Elacestrant (RAD1901): Radius Pharmaceuticals/ Menarini Group
• ZB716: Zenopharm
• ARV-471: Arvinas
• Lasofoxifene: Sermonix Pharmaceuticals
• H3B-6545: H3 Biomedicine/ Eisai
• SCO-120: Sun Pharma Advanced Research Company
• OP1250: Olema Pharmaceuticals
• Camizestrant (AZD983): AstraZeneca

ESR1 Mutated Metastatic Breast Cancer Market Strengths

• The rising incidence of ER+ breast cancer worldwide along with a rise in the use of endocrine drugs, will contribute to the rise in the incidence ofESR1 mutant breast cancer and, thus, the surge in treatment options
• The emergence in clinical trials activity for emerging therapies will boost the market
• Shortfall of approved therapies and effective therapies might provide good space for emerging therapies in the market
• Rising awareness about the disease among researchers, clinicians and patient

Scope of the ESR1 Mutated Metastatic Breast Cancer Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key ESR1 Mutated Metastatic Breast Cancer Companies: Radius Pharmaceuticals/ Menarini Group, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, Eisai, Sun Pharma Advanced Research Company, Olema Pharmaceuticals, AstraZeneca, and others
• Key ESR1 Mutated Metastatic Breast Cancer Therapies: Elacestrant (RAD1901), ZB716, ARV-471, Lasofoxifene, H3B-6545, SCO-120, OP1250, Camizestrant (AZD983), and others
• ESR1 Mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1 Mutated Metastatic Breast Cancer current marketed and ESR1 Mutated Metastatic Breast Cancer emerging therapies
• ESR1 Mutated Metastatic Breast Cancer Market Dynamics: ESR1 Mutated Metastatic Breast Cancer market drivers and ESR1 Mutated Metastatic Breast Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• ESR1 Mutated Metastatic Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, ESR1 Mutated Metastatic Breast Cancer Market Access and Reimbursement 

ESR1 Mutated Metastatic Breast Cancer Market Opportunities

• No effective approved treatment options offer a great opportunity for the investment and development of novel therapies
• Medications with better safety and effectiveness, which provide anoptimum cure, are the current unmet need of the ESR1 mutant breast cancer diseases market
• There is a need to focus on therapies with better compliance

Table of Contents 

1. ESR1 Mutated Metastatic Breast Cancer Market Report Introduction

2. Executive Summary for ESR1 Mutated Metastatic Breast Cancer

3. SWOT analysis of ESR1 Mutated Metastatic Breast Cancer

4. ESR1 Mutated Metastatic Breast Cancer Patient Share (%) Overview at a Glance

5. ESR1 Mutated Metastatic Breast Cancer Market Overview at a Glance

6. ESR1 Mutated Metastatic Breast Cancer Disease Background and Overview

7. ESR1 Mutated Metastatic Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of ESR1 Mutated Metastatic Breast Cancer 

9. ESR1 Mutated Metastatic Breast Cancer Current Treatment and Medical Practices

10. ESR1 Mutated Metastatic Breast Cancer Unmet Needs

11. ESR1 Mutated Metastatic Breast Cancer Emerging Therapies

12. ESR1 Mutated Metastatic Breast Cancer Market Outlook

13. Country-Wise ESR1 Mutated Metastatic Breast Cancer Market Analysis (2019–2032)

14. ESR1 Mutated Metastatic Breast Cancer Market Access and Reimbursement of Therapies

15. ESR1 Mutated Metastatic Breast Cancer Market Drivers

16. ESR1 Mutated Metastatic Breast Cancer Market Barriers

17.  ESR1 Mutated Metastatic Breast Cancer Appendix

18. ESR1 Mutated Metastatic Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about ESR1 Mutated Metastatic Breast Cancer treatment, visit @ ESR1 Mutated Metastatic Breast Cancer Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions